贝那利珠单抗--一种针对 IL-5Rα 的人源化 mAb，具有增强的抗体依赖性细胞介导的细胞毒性--治疗哮喘的一种新方法。
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
机构信息
University of Texas Medical Branch, Division of Allergy and Clinical Immunology, 4.118 John Sealy Annex, 301 University Blvd, Galveston, TX 77555-0568, USA.
出版信息
Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.
Abstract
INTRODUCTION
Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5.
AREAS COVERED
This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies.
EXPERT OPINION
Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
摘要
简介
本那鲁单抗是一种单克隆抗体，可与 IL-5 的 α 亚基结合。由于 IL-5 参与了由嗜酸性粒细胞介导的疾病状态，因此本那鲁单抗是管理哮喘的一种有吸引力的选择。由于增强了抗体定向细胞细胞毒性，与针对 IL-5 的中和单克隆抗体相比，它具有增强的嗜酸性粒细胞耗竭活性。
涵盖领域
本综述介绍了本那鲁单抗的现有数据，包括药效学、药代动力学、临床前数据和相关临床研究。
专家意见
我们的综述表明，尽管需要进一步研究来证明临床获益，但本那鲁单抗仍然是一种很有前途的治疗方式。
相似文献
1
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.
2
Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Int Rev Immunol. 2016 Jul 3;35(4):294-311. doi: 10.3109/08830185.2015.1128901. Epub 2016 Apr 27.
3
Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Front Immunol. 2021 Jan 8;11:593748. doi: 10.3389/fimmu.2020.593748. eCollection 2020.
4
Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Respir Med. 2019 Nov-Dec;160:105819. doi: 10.1016/j.rmed.2019.105819. Epub 2019 Nov 11.
5
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24.
6
Reductions in eosinophil biomarkers by benralizumab in patients with asthma.
Respir Med. 2016 Feb;111:21-9. doi: 10.1016/j.rmed.2016.01.003. Epub 2016 Jan 8.
7
Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Expert Rev Respir Med. 2020 Apr;14(4):353-365. doi: 10.1080/17476348.2020.1718495. Epub 2020 Jan 23.
8
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.
J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.
9
Benralizumab for the treatment of asthma.
Drugs Today (Barc). 2017 Dec;53(12):633-645. doi: 10.1358/dot.2017.53.12.2736670.
10
Benralizumab as a potential treatment of asthma.
Expert Opin Biol Ther. 2017 Jul;17(7):895-900. doi: 10.1080/14712598.2017.1319471. Epub 2017 Apr 19.
引用本文的文献
1
Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.
Biomolecules. 2025 Apr 8;15(4):544. doi: 10.3390/biom15040544.
2
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.
Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729.
3
Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis.
Biomedicines. 2025 Jan 15;13(1):197. doi: 10.3390/biomedicines13010197.
4
Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma.
J Clin Med. 2024 Dec 31;14(1):191. doi: 10.3390/jcm14010191.
5
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events.
J Immunother Cancer. 2024 Oct 12;12(10):e009658. doi: 10.1136/jitc-2024-009658.
6
Novel and potential future therapeutic options in systemic autoimmune diseases.
Front Immunol. 2024 Mar 15;15:1249500. doi: 10.3389/fimmu.2024.1249500. eCollection 2024.
7
Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles.
Life (Basel). 2024 Mar 7;14(3):350. doi: 10.3390/life14030350.
8
The Evolution of Scientific Knowledge in Childhood Asthma over Time: A Surprising History.
Children (Basel). 2024 Feb 18;11(2):262. doi: 10.3390/children11020262.
9
Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report.
BMC Geriatr. 2024 Jan 24;24(1):92. doi: 10.1186/s12877-024-04683-1.
10
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
Clin Rev Allergy Immunol. 2023 Dec;65(3):331-353. doi: 10.1007/s12016-023-08973-1. Epub 2023 Oct 28.
本文引用的文献
1
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.
J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.
2
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.
J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244.e2. doi: 10.1016/j.jaci.2010.04.005.
3
A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048.
4
Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity.
Hum Antibodies. 2009;18(1-2):17-27. doi: 10.3233/HAB-2009-0198.
5
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.
6
Mepolizumab and exacerbations of refractory eosinophilic asthma.
N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991.
7
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4. doi: 10.1016/j.jaci.2008.02.033. Epub 2008 Apr 14.
8
Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.
J Biol Chem. 2008 May 9;283(19):13398-406. doi: 10.1074/jbc.M710230200. Epub 2008 Mar 7.
9
Eosinophil trafficking in allergy and asthma.
J Allergy Clin Immunol. 2007 Jun;119(6):1303-10; quiz 1311-2. doi: 10.1016/j.jaci.2007.03.048. Epub 2007 May 3.
10
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. doi: 10.1164/rccm.200208-789OC. Epub 2002 Oct 17.
Zotero 插件